Qiagen N.V. (QGEN) 20.55 $QGEN
Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.
QIAGEN Down 9.4% Since SmarTrend Downtrend Call (QGEN)
Comtex SmarTrend(R) - Fri Apr 11, 11:19AM CDT
SmarTrend identified a Downtrend for QIAGEN (NASDAQ:QGEN) on January 29th, 2014 at $22.71. In approximately 2 months, QIAGEN has returned 9.42% as of today's recent price of $20.57.
QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders
PR Newswire - Thu Apr 10, 3:00PM CDT
ï"
QIAGEN N.V. to Report First Quarter 2014 Results and Hold Webcast
GlobeNewswire - Wed Apr 09, 6:26AM CDT
QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the first quarter 2014 on Tuesday, May 6, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET).
Mintz Levin Represents QIAGEN N.V. in Major Convertible Note Offering
Business Wire - Fri Apr 04, 11:53AM CDT
Attorneys in the Corporate & Securities and Life Sciences Practices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., together with European counsel, recently represented QIAGEN N.V. in a major offering of convertible notes. The transactions included the simultaneous repurchase from non-U.S. holders of approximately $291 million of outstanding convertible notes, the issuance of $730 million aggregate principal amount of new senior unsecured cash-settled convertible notes outside the United States, and the implementation of a call spread overlay increasing the effective strike price of the new convertible notes from QIAGEN's perspective.
QIAGEN Expands Product Portfolio for Next-generation Sequencing with QIAxpert® System and CLC Bioinformatics Suite for Cancer Research
PR Newswire - Thu Apr 03, 12:30AM CDT
ï"
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Qiagen's QuantiFERON-TB Test Now in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:43PM CDT
Qiagen plans to launch QuantiFERON-TB Gold In-Tube in China.
QIAGEN Launches QuantiFERON-TB Gold In-Tube in China to Aid Tuberculosis Control in Country with the Second-largest TB Burden
PR Newswire - Thu Mar 20, 1:55AM CDT
ï"
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Quarterly Changes to the NASDAQ Q-50 Index
GlobeNewswire - Mon Mar 17, 6:40AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, March 24, 2014.
QIAGEN N.V. Announces Successful Completion of Non-U.S. Offer Involving Convertible Notes
PR Newswire Europe - Wed Mar 12, 6:50PM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
QIAGEN N.V. Announces Successful Completion of
PR Newswire Europe - Wed Mar 12, 5:52PM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
QIAGEN N.V. Announces Terms of New Convertible Notes
PR Newswire Europe - Wed Mar 12, 10:39AM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
Dividend, Financial Results, Publishing of Clinical Study Data, New Offerings and Conference Call Schedules - Analyst Notes on H&R Block, Ulta Beauty, Myriad, QIAGEN, and Nutrisystem
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding H&R Block Inc. (NYSE: HRB), Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ: ULTA), Myriad Genetics, Inc. (NASDAQ: MYGN), QIAGEN NV (NASDAQ: QGEN), and Nutrisystem Inc. (NASDAQ: NTRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
QIAGEN N.V. Announces Non-U.S. Offer Involving Convertible Notes
PR Newswire Europe - Wed Mar 12, 3:18AM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.
QIAGEN Down 9.4% Since SmarTrend Downtrend Call (QGEN)
Comtex SmarTrend(R) - Fri Apr 11, 11:19AM CDT
SmarTrend identified a Downtrend for QIAGEN (NASDAQ:QGEN) on January 29th, 2014 at $22.71. In approximately 2 months, QIAGEN has returned 9.42% as of today's recent price of $20.57.
QIAGEN Adds Promising New Biomarker to Pipeline of Personalized Healthcare Assays to Improve Diagnosis of Blood Disorders
PR Newswire - Thu Apr 10, 3:00PM CDT
ï"
QIAGEN N.V. to Report First Quarter 2014 Results and Hold Webcast
GlobeNewswire - Wed Apr 09, 6:26AM CDT
QIAGEN N.V. (Nasdaq:QGEN) (Frankfurt:QIA) today reconfirmed plans to release its report on results for the first quarter 2014 on Tuesday, May 6, at 22:00 Central European Time (CET) / 16:00 Eastern Time (ET).
Mintz Levin Represents QIAGEN N.V. in Major Convertible Note Offering
Business Wire - Fri Apr 04, 11:53AM CDT
Attorneys in the Corporate & Securities and Life Sciences Practices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., together with European counsel, recently represented QIAGEN N.V. in a major offering of convertible notes. The transactions included the simultaneous repurchase from non-U.S. holders of approximately $291 million of outstanding convertible notes, the issuance of $730 million aggregate principal amount of new senior unsecured cash-settled convertible notes outside the United States, and the implementation of a call spread overlay increasing the effective strike price of the new convertible notes from QIAGEN's perspective.
QIAGEN Expands Product Portfolio for Next-generation Sequencing with QIAxpert® System and CLC Bioinformatics Suite for Cancer Research
PR Newswire - Thu Apr 03, 12:30AM CDT
ï"
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Qiagen's QuantiFERON-TB Test Now in China - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:43PM CDT
Qiagen plans to launch QuantiFERON-TB Gold In-Tube in China.
QIAGEN Launches QuantiFERON-TB Gold In-Tube in China to Aid Tuberculosis Control in Country with the Second-largest TB Burden
PR Newswire - Thu Mar 20, 1:55AM CDT
ï"
Predictive Diagnostics - Global Strategic Business Report
M2 - Tue Mar 18, 7:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvpvwm/predictive) has announced the addition of the "Predictive Diagnostics - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Predictive Diagnostics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 58 companies including many key and niche players such as: - Abbott Molecular - Almac Group Ltd. - BioGenex - Covance, Inc. - Dako Denmark A/S - Epistem Plc - F. Hoffmann-La Roche Ltd. - Genomic Health, Inc. - MDxHEALTH, Inc. - Myriad Genetics, Inc. - Precision Therapeutics, Inc. - Prometheus Laboratories - QIAGEN N.V. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. Executive Summary 1. INDUSTRY OVERVIEW 2. MAJOR MARKET TRENDS, DRIVERS & ISSUES 3. PRODUCT OVERVIEW 4. RECENT INDUSTRY ACTIVITY 5. FOCUS ON SELECT PLAYERS 6. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. REST OF WORLD IV. COMPETITIVE LANDSCAPE Total Companies Profiled: 58 (including Divisions/Subsidiaries - 61) - The United States (31) - Canada (2) - Europe (19) - Germany (4) - The United Kingdom (7) - Spain (1) - Rest of Europe (7) - Asia-Pacific (Excluding Japan) (7) - Middle East (2) For more information visit http://www.researchandmarkets.com/research/dvpvwm/predictive
Quarterly Changes to the NASDAQ Q-50 Index
GlobeNewswire - Mon Mar 17, 6:40AM CDT
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the quarterly re-ranking of the NASDAQ Q-50 Index (Nasdaq:NXTQ), which will become effective prior to market open on Monday, March 24, 2014.
QIAGEN N.V. Announces Successful Completion of Non-U.S. Offer Involving Convertible Notes
PR Newswire Europe - Wed Mar 12, 6:50PM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
QIAGEN N.V. Announces Successful Completion of
PR Newswire Europe - Wed Mar 12, 5:52PM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
QIAGEN N.V. Announces Terms of New Convertible Notes
PR Newswire Europe - Wed Mar 12, 10:39AM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
Dividend, Financial Results, Publishing of Clinical Study Data, New Offerings and Conference Call Schedules - Analyst Notes on H&R Block, Ulta Beauty, Myriad, QIAGEN, and Nutrisystem
PR Newswire - Wed Mar 12, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding H&R Block Inc. (NYSE: HRB), Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ: ULTA), Myriad Genetics, Inc. (NASDAQ: MYGN), QIAGEN NV (NASDAQ: QGEN), and Nutrisystem Inc. (NASDAQ: NTRI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
QIAGEN N.V. Announces Non-U.S. Offer Involving Convertible Notes
PR Newswire Europe - Wed Mar 12, 3:18AM CDT
HILDEN, Germany, March 12, 2014 /PRNewswire/ --
